{"transactions":[{"id":127450,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":12112,"kind":"organization","name":"Onyx Therapeutics, Inc.","position":1,"cik":"0001744260","reported_name":"Onyx Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2018-06-26T01:14:02.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":1121384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1121384},"source":{"system":"sec-edgar","filing":"0000899243-18-018026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924318018026/doc4.xml","form_type":"4"}},{"id":127449,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":12112,"kind":"organization","name":"Onyx Therapeutics, Inc.","position":1,"cik":"0001744260","reported_name":"Onyx Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T01:14:02.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1121384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":1121384,"source":{"system":"sec-edgar","filing":"0000899243-18-018026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000089924318018026/doc4.xml","form_type":"4"}}]}